Trade

with

Oramed Pharmaceuticals Inc
(NASDAQ: ORMP)
AdChoices
8.00
+0.17
+2.17%
After Hours :
8.49
+0.49
+6.13%

Open

7.86

Previous Close

7.83

Volume (Avg)

21.15k (48.41k)

Day's Range

7.81-8.19

52Wk Range

6.28-31.73

Market Cap.

79.65M

Dividend Rate ( Yield )

-

Beta

0.23

Shares Outstanding

9.96M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -4.23M

    • Market Cap.

    • 79.65M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.23

    • Forward P/E

    • -

    • Price/Sales

    • -

    • Price/Book Value

    • 3.62

    • Price/Cash flow

    • -19.34

      • EBITDA

      • -4.12M

      • Return on Capital %

      • -35.53

      • Return on Equity %

      • -37.18

      • Return on Assets %

      • -35.53

      • Book Value/Share

      • 2.21

      • Shares Outstanding

      • 9.96M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 32.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 32.26

              • 2.92

              • Quick Ratio

              • 31.94

              • 2.35

              • Interest Coverage

              • 333.32

              • 38.02

              • Leverage Ratio

              • 1.02

              • 2.21

              • Book Value/Share

              • 2.21

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -14.12

                • 217.39

                • P/E Ratio 5-Year High

                • -56.40

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.27

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.52

                • Price/Book Value

                • 3.60

                • 8.61

                • Price/Cash Flow Ratio

                • -19.34

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -37.18

                    (-94.10)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -35.53

                    (-74.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -37.30

                    (-96.60)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -4.30M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -19.34
                  Ownership

                  Institutional Ownership

                  28.18%

                  Top 10 Institutions

                  31.40%

                  Mutual Fund Ownership

                  3.46%

                  Float

                  77.71%

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • MassMutual Select Small Cap Growth Eq

                  •  

                    101,754

                  • -7.79

                  • 1.01

                  • SEI Small/Mid Cap Equity (SIIT)

                  •  

                    84,826

                  • 0.00

                  • 0.84

                  • SEI Small Cap (SIIT)

                  •  

                    41,854

                  • 0.00

                  • 0.42

                  • SEI Small Cap (SIMT)

                  •  

                    31,238

                  • 0.00

                  • 0.31

                  • MassMutual Select Small Company Growth

                  •  

                    28,414

                  • -10.12

                  • 0.28

                  • SEI Small Cap II (SIIT)

                  •  

                    23,690

                  • 0.00

                  • 0.24

                  • Montibus Small Cap Growth Fund

                  •  

                    17,782

                  • 88.07

                  • 0.18

                  • SEI Small Cap Growth (SIMT)

                  •  

                    16,059

                  • 0.00

                  • 0.16

                  • Fidelity® NASDAQ Composite Index® Fund

                  •  

                    1,051

                  • 0.00

                  • 0.01

                  • FlexShares Mstar US Mkt Factors Tilt ETF

                  •  

                    1,032

                  • 0.00

                  • 0.01

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Regals Management LP

                  •  

                    1,376,385

                  • +80.95%

                  • 17.32

                  • Awm Investment Company Inc

                  •  

                    790,000

                  • 0.00%

                  • 7.94

                  • Montibus Capital Management LLC

                  •  

                    413,664

                  • +64.70%

                  • 4.15

                  • Greylin Investment Mangement Inc

                  •  

                    91,200

                  • +7.42%

                  • 0.92

                  • Susquehanna Financial Group, LLLP

                  •  

                    28,579

                  • +17.70%

                  • 0.29

                  • Tocqueville Asset Management L.P.

                  •  

                    15,000

                  • 0.00%

                  • 0.15

                  • HSBC Holdings PLC

                  •  

                    15,000

                  • 0.00%

                  • 0.15

                  • Morgan Stanley & Co Inc

                  •  

                    8,863

                  • +1.54%

                  • 0.09

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Oramed Pharmaceuticals Inc. was incorporated on April 12, 2002, under the laws of the State of Nevada. It is a pharmaceutical Company engaged in the research and development of innovative pharmaceutical solutions, including an orally...more ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. The Company is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD0801) currently in Phase 2 clinical trials. The Company plans to continue to conduct clinical trials to show the effectiveness of its technology. It filed two...more additional provisional patents for a suppository application to its technology portfolio. The first patent focuses on a rectal application for insulin. The second patent focuses on the usage of this rectal application to other polypeptides that at present are only available in injection. On September 16, 2008 it announced the launch of pre-clinical trials of ORMD 0901, a GLP1-analog. The Company has agreements with Vetgenerics Research G. Ziv Ltd., a clinical research organization, to conduct a toxicology trial on its oral insulin capsules. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.lessless

                  Key People

                  Mr. Nadav Kidron

                  CEO/President/Director

                  Yifat Zommer

                  CFO/Chief Accounting Officer/Secretary/Treasurer

                  Leonard Sank

                  Director

                  Dr. Miriam Kidron,PhD

                  Director/Chief Medical Officer/Chief Technology Officer

                  Harold Jacob

                  Director

                  • Oramed Pharmaceuticals Inc

                  • Hi-Tech Park 2/4

                  • Jerusalem, 91390

                  • USA.Map

                  • Phone: +972 25660001

                  • Fax: +972 25660004

                  • oramed.com

                  Incorporated

                  2002

                  Employees

                  10

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: